

Xuhong Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3571159/publications.pdf>

Version: 2024-02-01

58
papers

12,460
citations

101496

36
h-index

155592

55
g-index

58
all docs

58
docs citations

58
times ranked

21683
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
2	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , 2015, 47, 199-208.	9.4	2,410
3	The Landscape of Circular RNA in Cancer. <i>Cell</i> , 2019, 176, 869-881.e13.	13.5	1,095
4	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014, 510, 278-282.	13.7	811
5	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	13.7	685
6	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451
7	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018, 173, 1770-1782.e14.	13.5	400
8	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 913.	3.8	333
9	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , 2015, 75, 3720-3727.	0.4	276
10	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017, 171, 1559-1572.e20.	13.5	200
11	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016, 7, 12791.	5.8	196
12	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
13	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. <i>Nature</i> , 2019, 571, 413-418.	13.7	192
14	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015, 21, 344-352.	15.2	165
15	The landscape of antisense gene expression in human cancers. <i>Genome Research</i> , 2015, 25, 1068-1079.	2.4	150
16	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw200.	3.0	150
17	Targeting transcriptional regulation of SARS-CoV-2 entry factors <i>ACE2</i> and <i>TMPRSS2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	142
18	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , 2015, 25, 1372-1381.	2.4	139

#	ARTICLE	IF	CITATIONS
19	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	136
20	The central role of EED in the orchestration of polycomb group complexes. <i>Nature Communications</i> , 2014, 5, 3127.	5.8	130
21	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. <i>Nature Communications</i> , 2014, 5, 5893.	5.8	121
22	The lncRNA <i>PCAT29</i> Inhibits Oncogenic Phenotypes in Prostate Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 1081-1087.	1.5	119
23	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. <i>Nature</i> , 2022, 601, 434-439.	13.7	110
24	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , 2020, 22, 111-119.	2.3	101
25	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. <i>Science Translational Medicine</i> , 2014, 6, 252ra122.	5.8	86
26	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 483-486.	0.9	86
27	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 532-548.e7.	7.7	85
28	Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 696-707.	3.2	80
29	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016, 17, 2620-2631.	2.9	68
30	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	3.4	65
31	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. <i>European Urology</i> , 2020, 78, 63-74.	0.9	57
32	De novo dominant <i>ASXL3</i> mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 597-608.	1.4	56
33	Identification and Validation of <i>PCAT14</i> as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 489-499.	2.3	55
34	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 978-993.	5.7	52
35	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <i>European Urology Focus</i> , 2016, 1, 265-268.	1.6	45
36	Clinical validation of the Tempus xO assay. <i>Oncotarget</i> , 2018, 9, 25826-25832.	0.8	43

#	ARTICLE	IF	CITATIONS
37	KRAS Engages AGO2 to Enhance Cellular Transformation. <i>Cell Reports</i> , 2016, 14, 1448-1461.	2.9	41
38	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA <i>in Situ</i> Hybridization Assay. <i>Clinical Cancer Research</i> , 2017, 23, 5622-5630.	3.2	31
39	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. <i>Nature Communications</i> , 2020, 11, 2817.	5.8	29
40	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4038-4048.	3.2	26
41	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016, 18, 1-9.	2.3	25
42	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. <i>Neoplasia</i> , 2018, 20, 1144-1149.	2.3	20
43	Next generation sequencing of extraskeletal myxoid chondrosarcoma. <i>Oncotarget</i> , 2017, 8, 21770-21777.	0.8	20
44	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. <i>Oncotarget</i> , 2016, 7, 52888-52899.	0.8	18
45	Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. <i>Npj Precision Oncology</i> , 2017, 1, 32.	2.3	17
46	Genetic diversity of NDUFV1-dependent mitochondrial complex I deficiency. <i>European Journal of Human Genetics</i> , 2018, 26, 1582-1587.	1.4	15
47	AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
48	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	2.2	12
49	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-34.	1.5	10
50	Characterizing the Therapeutic Potential of a Potent BET Degradar in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 322-330.	2.3	10
51	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 641-652.	0.3	9
52	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3079-3093.	3.2	8
53	Tomlins et al. reply. <i>Nature</i> , 2009, 457, E2-E3.	13.7	6
54	Identification of clinically actionable pharmacogenetic variants during tumor genetic profiling in pediatric cancer patients. <i>Journal of Clinical Oncology</i> , 2016, 34, 1583-1583.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Comprehensive molecular profiling of pretreatment metastatic castration resistant prostate cancer (CRPC): Secondary data from NCI 9012, a randomized ETS fusion-stratified phase II trial.. Journal of Clinical Oncology, 2014, 32, e16038-e16038.	0.8	1
56	DIPG-38. ID1 EXPRESSION CORRELATES WITH H3F3A K27M MUTATION AND EXTRA-PONTINE INVASION IN DIPG. Neuro-Oncology, 2018, 20, i56-i56.	0.6	0
57	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. Blood, 2015, 126, 647-647.	0.6	0
58	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. Neuro-Oncology, 2020, 22, iii298-iii299.	0.6	0